Generic Oncology Sterile Injectables - Revenue Opportunities By Top Key Vendors of Global Market | Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC

Generic Oncology Sterile Injectables are used in treatment of various types of cancers such as ovarian, breast, and lung. These drugs are relatively cheaper than branded counterparts. This is owing presence of same active ingredients, although its inactive contents are different. Cost is a major concern for cancer patients, especially in emerging economies such as India, Brazil, and China. Therefore, governments of such countries are taking efforts to reduce cost of medications and increase its accessibility. For instance, the National Pharmaceutical Pricing Authority (NPPA) of India reduced the prices of a few cancer drugs by 86% in March 2017.

Download PDF Brochure of Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/562

The key players in generic oncology sterile injectable market includes, Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.

Rising number of cancer cases is expected to fuel demand for treatment drugs and injectables. According to the World Cancer Research Fund International (WCRFI), around 14.1 million cancer cases were reported worldwide, in 2012. As per WCRFI, it is projected that by 2035, around 24 million cancer cases are expected to increase. This is expected to drive growth of the generic oncology sterile injectable market.

The global generic oncology sterile injectable market was valued at US$ 8.9 Billion in 2016 and is expected to exhibit a CAGR of 11.4% over the forecast period (2017–2025).
Generic oncology sterile injectables have a huge potential in such countries, where patient population is high; however, spending power is relatively low. Furthermore, patent expiry is expected to fuel growth of the generic oncology sterile injectables during the forecast period. Also, the emergence of biosimilars has also impacted growth of generics drugs. For instance, according to the Journal of Generics and Biosimilars Initiative, 2017, biosimilars had a major share in Europe since 2013 and in the U.S. since 2015 and the share of biosimilars is expected to increase significantly in the biologicals market. This is expected to eventually boost growth of the generic oncology sterile injectable market.

Market Dynamics
Generic oncology sterile injectables market is gaining significant traction due to rising prevalence of cancer cases. For instance, according to the National Cancer Institute, in 2016, around 1,685,210 new cases of cancers were reported in the U.S. Manufacturers are focusing on launching new products to offer low cost treatment to patients. For instance, in November, 2017, Mylan N.V. launched Clofarabine Injection (20 mg/20 mL (1 mg/mL) Single-Dose Vials) following U.S. Food and Drug administration approval in the U.S. market. Clofarabine is a generic version of Genzyme's Clolar, which is used for treatment of refractory acute lymphoblastic leukemia for patients aged 1 year to 21 years.

Request for Customization of Research Report:
https://www.coherentmarketinsights.com/insight/request-customization/562

Key features of the study:
• This report provides in-depth analysis of the generic oncology sterile injectables market and its product type, market size (US$ Million), and Cumulative Annual Growth Rate (CAGR %) for the forecast period: 2017 – 2025, considering 2016as the base year.
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players.
• It profiles leading players in the generic oncology sterile injectables market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans.
• Key companies covered as a part of this study include Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, distribution channel, market expansion, and marketing tactics.
• The generic oncology sterile injectables market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for generic oncology sterile injectables market, research and consulting firms, new entrants and financial analysts.
• Various strategy matrices used in analyzing the generic oncology sterile injectables market would provide stakeholders vital inputs to make strategic decisions accordingly.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.